Conroy et al. (May 12 issue)1 report that FOLFIRINOX (a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin) provided a statistically and clinically significant benefit over single-agent gemcitabine in patients with advanced pancreatic cancer. Although the increased toxicity associated with this combination therapy may temper enthusiasm, this is the first real advance in such therapy since the introduction of gemcitabine.
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
michele Milella
2011-01-01
Abstract
Conroy et al. (May 12 issue)1 report that FOLFIRINOX (a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin) provided a statistically and clinically significant benefit over single-agent gemcitabine in patients with advanced pancreatic cancer. Although the increased toxicity associated with this combination therapy may temper enthusiasm, this is the first real advance in such therapy since the introduction of gemcitabine.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
nejmc1107627.pdf
accesso aperto
Licenza:
Dominio pubblico
Dimensione
316.43 kB
Formato
Adobe PDF
|
316.43 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
